RAS, wanted dead or alive: Advances in targeting RAS mutant cancers

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Oncogenic RAS proteins are mutated in ~24% of human cancers, historically deemed
• undruggable" therapeutic targets.
• Recent advancements include clinical evaluation of small molecules targeting specific oncogenic RAS mutants (e.g., G12C).
• Growing understanding reveals differential impacts of various RAS isoforms (HRAS, NRAS, KRAS4A/KRAS4B) and mutations (Gly12, Gly13, Gln61) on cellular signaling.

Purpose of the Study:

• To review current trends and strategies in targeting oncogenic RAS proteins for cancer therapy.
• To highlight novel approaches beyond directly inhibiting mutated RAS.
• To discuss the evolving landscape of anti-RAS therapeutic development.

Main Methods:

• Review of recent scientific literature and clinical trial data.
• Analysis of emerging therapeutic strategies targeting RAS signaling pathways.
• Synthesis of information on novel drug development and biological insights.

Main Results:

• Development of small molecules targeting specific RAS mutations (e.g., KRAS G12C) is progressing.
• New strategies focus on targeting wild-type RAS interactions with guanine nucleotide exchange factors (GEFs).
• Inhibition of receptor tyrosine kinase-mediated RAS activation and downstream effectors shows promise.

Conclusions:

• RAS proteins, despite their challenging nature, are becoming increasingly druggable.
• Targeting RAS signaling pathways offers diverse therapeutic opportunities in oncology.
• Continued research into RAS biology and effector pathways is crucial for advancing cancer treatment.